Published in Haemophilia on September 01, 2002
Quantitation of anti-factor VIII antibodies in human plasma. Blood (2009) 0.97
ELISA for factor VIII antibodies: does it detect antibodies much before the conventional Bethesda assay? Haemophilia (2003) 0.76
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus (2015) 0.75
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med (1990) 2.25
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost (2012) 1.74
Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg (1988) 1.53
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients. Haemophilia (2001) 1.40
[A complication in Budd-Chiari syndrome. Heparin therapy caused thrombocytopenia]. Lakartidningen (1994) 1.39
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol (1999) 1.32
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med (1991) 1.30
Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril (1994) 1.22
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) (1985) 1.19
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism (1990) 1.12
ADP-induced platelet aggregation as a function of age in healthy humans. Thromb Haemost (1989) 1.08
Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol (1998) 1.02
A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost (1996) 1.01
Normal vaginal delivery is to be recommended for haemophilia carrier gravidae. Acta Paediatr (1994) 1.01
von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis. Ann Rheum Dis (1991) 0.99
Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I. Blood Coagul Fibrinolysis (1996) 0.99
Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest (1982) 0.97
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol (2001) 0.96
High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb (1994) 0.96
Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol (2001) 0.96
A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol (2000) 0.94
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia (2004) 0.93
Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma (1996) 0.93
Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost (1997) 0.93
Cytokine release during long-term extracorporeal circulation in an experimental model. Artif Organs (1998) 0.92
Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost (1989) 0.91
Haematological changes during acute mental stress. Br J Haematol (1989) 0.90
Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol (1995) 0.89
Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost (1996) 0.87
The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost (1994) 0.87
Nitric oxide in the oxygenator sweep gas reduces platelet activation during experimental perfusion. Ann Thorac Surg (1996) 0.86
Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase. J Inherit Metab Dis (1989) 0.86
APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost (1999) 0.85
Plasma homocysteine in venous thromboembolism. Haemostasis (1991) 0.84
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia (2003) 0.84
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost (1995) 0.84
Platelet reactivity, fibrinogen and smoking. Eur J Haematol (1987) 0.83
Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost (1992) 0.83
Apnoea and bradycardia from submersion in "chronically" decerebrated cats. Acta Physiol Scand (1977) 0.83
The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost (1991) 0.83
Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. Eur J Haematol (1998) 0.82
Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr (1992) 0.82
Blood group A antigen expression in platelets is prominently associated with glycoprotein Ib and IIb. Evidence for an A1/A2 difference. Transfus Med (1996) 0.82
Multiple quinine-dependent antibodies in a patient with episodic thrombocytopenia, neutropenia, lymphocytopenia, and granulomatous hepatitis. Blood (1997) 0.82
Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. Risk Factor Intervention Study Group. J Intern Med (1995) 0.81
Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am (1991) 0.80
Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation (1990) 0.80
Femoral artery wall morphology, hemostatic factors and intermittent claudication: ultrasound study in men at high and low risk for atherosclerotic disease. Haemostasis (1996) 0.80
Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis (1989) 0.80
Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies. Int J Artif Organs (1995) 0.80
Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost (1992) 0.80
The effect of albumin priming solution on platelet activation during experimental long-term perfusion. Perfusion (1998) 0.80
Metformin and metoprolol CR treatment in non-obese men. J Intern Med (1994) 0.79
Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol (1995) 0.79
Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr (1998) 0.79
Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis. Eur J Haematol (1996) 0.79
Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol (2000) 0.79
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro. Leukemia (2010) 0.79
'Polycythaemia of stress' in subjects with Type A and Type B behaviour patterns. J Psychosom Res (1991) 0.78
Regional fibrinolysis following total hip replacement. Thromb Res (1991) 0.78
Effect of nitric oxide gas on platelets during open heart operations. Ann Thorac Surg (1998) 0.78
Heparin-induced thrombocytopenia during continuous haemofiltration. Nephrol Dial Transplant (1995) 0.78
Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. Eur J Haematol (1996) 0.78
Hemostatic responses to mental stress during the menstrual cycle. Thromb Haemost (1991) 0.78
Postoperative autotransfusion of concentrated drainage blood in cardiac surgery. Experience with a new autotransfusion system. Scand J Thorac Cardiovasc Surg (1987) 0.78
Evidence for an expression of blood group A antigen on platelet glycoproteins IV and V. Transfus Med (1996) 0.78
Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol (1998) 0.77
The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia. Leuk Lymphoma (2001) 0.77
The measurement of venous haematocrit in patients with polycythaemia vera. J Intern Med (1999) 0.77
Immunoglobulins targeting both GPIIb/IIIa and GPIb/IX in chronic idiopathic thrombocytopenic purpura (ITP): evidence for at least two different IgG antibodies. Br J Haematol (1997) 0.77
The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol (1997) 0.77
Management of haemophilia A with antibodies--the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide. Thromb Haemost (1985) 0.77
Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol (1996) 0.77
[New in vitro analysis tested: bleeding time is still the best method for evaluation of primary hemostasis]. Lakartidningen (2001) 0.77
[A case report. Thrombocytopenia and granulomatous hepatitis caused by quinine]. Lakartidningen (1996) 0.77
Reduction in deposition of indium 111-labeled platelets after autologous endothelial cell seeding of Dacron aortic bifurcation grafts in humans: a preliminary report. J Vasc Surg (1987) 0.77
Platelet activation and degradation in an experimental extracorporeal system. A comparison between a silicone membrane and a hollow-fibre oxygenator. Perfusion (1996) 0.77
The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis (1999) 0.77
Soluble saccharides block the inhibition of agonist-induced human platelet aggregation observed after in vitro incubation of human platelet-rich plasma with porcine aortic endothelial cells. Transpl Int (1998) 0.76
Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency. Scand J Clin Lab Invest (1981) 0.76
Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med (2000) 0.76
Comparison of various D-dimer tests for the diagnosis of deep venous thrombosis. Blood Coagul Fibrinolysis (1999) 0.76
Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis. Hum Genet (1992) 0.76
Sudden sensorineural hearing loss and hemostatic mechanisms. Arch Otolaryngol Head Neck Surg (1994) 0.76
Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost (1994) 0.76
Antithrombin III concentrate. Thromboprophylaxis during pregnancy in a patient with congenital antithrombin III deficiency. Acta Obstet Gynecol Scand (1986) 0.76
Evidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP). Br J Haematol (1995) 0.76
Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Intern Med (1999) 0.76
Anti- and procoagulant activities in factor VII-deficient subjects. Thromb Res (2001) 0.76
Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg (1993) 0.76
Evaluation of platelet reactivity in diabetes mellitus. Acta Med Scand (1986) 0.76
Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency. Haemophilia (2003) 0.75
In vitro platelet function in infantile autism. Folia Haematol Int Mag Klin Morphol Blutforsch (1988) 0.75
The effect of centrifugation time and gravitational force on platelet yield and platelet volume distribution in platelet-rich plasma (PRP) obtained by differential centrifugation. Thromb Res (1991) 0.75
Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg (1995) 0.75
Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A? Thromb Haemost (2000) 0.75
Factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 0.75